Quantitative structure-activity relationship modeling of dermatomyositis activity of drug chemicals

Arzneimittel-Forschung/Drug Research

Volumn 56, Issue 12, 2006, Pages 856-865

  Kamenska, Verginia ^a   Dourmishev, Lyubomir ^b   Dourmishev, Assen ^b   Vasilev, Rusi ^a   Mekenyan, Ovanes ^a  

^a ASSEN ZLATAROV UNIVERSITY   (Bulgaria)

^b MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

Author keywords

Dermatomyositis; Drug modeling; Side effects

Indexed keywords

ACETYLSALICYLIC ACID; ANTAZOLINE; ANTIINFECTIVE AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; CARBONYL DERIVATIVE; CHLORPROMAZINE; CLEMIZOLE; DICLOFENAC; FENOFIBRATE; GEMFIBROZIL; HYDROXYL GROUP; HYDROXYUREA; ISONIAZID; MEVINOLIN; NITROGEN; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PENICILLAMINE DISULFIDE; PENICILLIN G; PHENYLBUTAZONE; PRAVASTATIN; SIMVASTATIN; SULFACETAMIDE; SULFUR; TAMOXIFEN; TEGAFUR; ZIDOVUDINE;

ARTICLE; ATOM; DERMATOMYCOSIS; DRUG ACTIVITY; ELECTROPHILIC STRESS; MOLECULAR MODEL; POLYMYOSITIS; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REDUCTION;

EID: 33845987396     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296798     Document Type: Article

References (33)

1. Bohan, A., Peter, J. B., Polymyositis and dermatomyositis. N. Engl. J. Med. 292, 345 (1975)
2. Dourmishev, A. L., Dourmishev, L. A., Dermatomyositis and Drugs, Adv. Exp. Med. Biol. 455, 187 (1999), in: Rheuma Derm, Mallia and Uitto (eds.), Kluwer Academic Press / Plenum Publishers, New York (1999)
3. Noël, B., Cerottini, J. P., Pires, A. et al., Atorvastatine et dermatomyositis. Ann. Dermatol. Venereol. 127, 4S77 (2000)
4. Ridriguez-Gacia, J. I., Serrano Commino, M., Lovastatin-associated dermatomyositis. Postgrad. Med. J. 72, 694 (1996)
5. Schalke, B. B., Schmidt, B., Toyka, K. et al., Pravastatin and dermatomyositis. N. Engl. J. Med. 111, 649 (1992)
6. Khattak, F. H., Moris, I. M., Branford, W. A., Simvastatin-associated dermatomyositis. Br. J. Rheumatol. 32, 199 (1994)
7. Sauvage, F., Piette, J. C., Herson, S. et al., Fenofibrate-induced polymyositis. Rev. Med. Interne 12, 52 (1991)
8. Fusella, J., Strosberg, J. M., Polymyositis exacerbated by gemfibrocil. J. Rheumatol. 17, 572 (1990)
9. Grob, J. J., Collet, A. M., Bonerandi, J. J., Dermatomyositis-like syndrome induced by nonsteroid anti-inflamatory agents. Dermatologica 178, 178 (1989)
10. Ross, N. S., Hoppel, C. L., Partial muscle carnitine palmitoyltransferase-A deficiency. Rhabdomyolysis associated with transiently decreased muscle carnitine content after ibuprofen therapy. JAMA 2, 257, 62 (1987)
11. Curran, J. J., Jamieson, T. W., Dermatomyositis-like syndrome associated with phenylbutazone therapy. J. Rheumatol. 14, 397 (1987)
12. Dourmishev, L. A., Stomonjakova, S. R., Dourmishev, A. L., D-Penicillamine induced polymyositis and morphea dissemination in woman with Hashimoto thyreoiditis. J. Eur. Acad. Dermatol. Venereol. 16, 538 (2002)
13. Shelly, W. B., Birch pollen and aspirin psoriasis. JAMA 189, 986 (1964)
14. Richard, M., Trucheter, F. Friedel, J. et al., Skin lesions simulating chronic dermatomyositis during long term hydroxyurea therapy. J. Am. Acad. Dermatol. 21, 797 (1989)
15. Harris, A. L., Smith, I. E., Snaith, M., Tamoxifen-induced tumor regression associated with dermatomyositis. Br. Med. J. 284, 1674 (1982)
16. Akiyama, C., Osada, A., Sou, K. et al., A case of dermatomyositis triggered by tegafur. Acta Derm. Venereol. (Stockh). 77, 490 (1997)
17. Parker, C. V., Drug allergy. New Engl. J. Med. 292, 511;
18. 732, 957 (1975)
19. Mackie, B. C., Mackie, L. E., Lupus erythematosus; dermatomyositis induced by sulphacetamide eye drops. Clin. Exp. Dermatol. 4, 111 (1979)
20. Fayolle, J., Vallon, C., Claudy, E. et al., Dermatomyositis indute par l'isoniazide. Lyon Med. 223, 135 (1975)
21. Hessen, L. J., Green, G. B., Louie, E. et al., Severe polymyositis-like syndrome associated with zidovudine therapy of AIDS and ARC. New Engl. J. Med. 318, 708 (1988)
22. Beickert, A., Kuhne, W., Dermatomyositis mit Immunleucopenie, Phenothiazinschädigung. Schweiz. Med. Wochenschr. 90, 132 (1960)
23. Mackie, B., Dermatomyositis induced by drugs. Aust. J. Dermatol. 8, 249 (1966)
24. Ivanov, J. M., Mekenyan, O. G., Bradbury, S. P. et al., A Kinetic Analysis of the Conformational Flexibility of Steroids. Quant. Struct. Act. Relat. 17, 437 (1998)
25. Mekenyan, O. G., Ivanov, J. M., Karabunarliev, S. et al., A Computationally-based Hazard Identification Algorithm That Incorporates Ligand Flexibility. Environ. Sci. Technol. 31, 3702 (1997)
26. Mekenyan, O. G., Nikolova, N., Karabunarliev, S. et al., New Developments in a Hazard Identification Algorithm For Hormone Receptor Ligands: COREPA-C. Quant. Struct. Act. Relat. 18, 139 (1999)
27. Mekenyan, O. G., Dimitrov, D., Nikolova N. et al., Conformational Coverage by a Genetic Algorithm. Chem. Inf. Comput. Sci. 39/6, 997 (1999)
28. Mekenyan, O. G., Nikolova, N., Schmieder, P., Dynamic 3D QSAR techniques applications in toxicology. J. Mol. Struct. (Theochem) 622, 147 (2003)
29. Mekenyan, O. G., Karabunarliev, S., Ivanov, J.M. et al., A New Development of the OASIS Computer System For Modeling Molecular Properties. Comput. Chem. 18, 173 (1994)
30. Ivanov, J. M., Karabunarliev, S., Mekenyan, O. G., 3DGEN: A System For an Exhaustive 3D Molecular Design. J. Chem. Inf. Comput. Chem. 34, 234 (1994)
31. Mekenyan, O. G., Pavlov, T., Grancharov, V. et al., 2D-3D Migration of Large Chemical Inventories with Conformational Multiplication. Application of the Genetic Algorithm. J. Chem. Inf. Model. 45, 283 (2005)
32. Stewart, J. J. P., MOPAC: A semiempirical molecular orbital program. J. Comput.-Aided Mol. Des. 4, 1 (1990)
33. Stewart, J. J. P., MOPAC 93. Fujitsu Limited, 9-3, Nakase 1-Chome, Mihama-ku, Chiba-city, Chiba 261, Japan, and Stewart Computational Chemistry. 15210 Paddington Circle, Colorado Springs, Colorado 80921, USA (1993)